Halting the Epidemic of Addiction and Loss Act of 2023 or the HEAL Act of 2023 This bill requires the Department of Health and Human Services (HHS) to ensure that references in its grant programs to opioid overdose reversal agents are inclusive of any such agents that have been approved by the Food and Drug Administration (FDA). Specifically, HHS must ensure that regulations, guidance, and other documents for grant programs that include references to opioid overdose reversal agents (e.g., naloxone) encompass any opioid overdose reversal agent that has been approved by the FDA. HHS must also update such references with respect to materials that were previously issued for State Opioid Response Grants, Tribal Opioid Response Grants, and Programs of Regional and National Significance for substance use disorder prevention.